Checkpoint Therapeutics announced that the U.S. Patent and Trademark Office, USPTO, has issued a new patent covering a method of treating various cancers, including cutaneous squamous cell carcinoma, through the administration of cosibelimab. The USPTO previously issued a composition of matter patent, specifically covering cosibelimab, or a fragment thereof. Together, these patents protect Checkpoint’s differentiated and potential best-in-class anti-PD-L1 antibody, cosibelimab, in the U.S. through at least May 2038, not including any potential patent term extension under the Hatch-Waxman Act. “With less than five weeks remaining before our assigned PDUFA date for cosibelimab, we look forward to cosibelimab potentially joining an approved class of immunotherapies with combined worldwide annual sales exceeding $35 billion,” said James Oliviero, President and Chief Executive Officer of Checkpoint. “We believe our broad U.S. patent portfolio, expiring no earlier than May 2038, provides the potential for cosibelimab to be further developed into a market leading drug, not only in cSCC, but also in additional indications, both as a monotherapy and as the PD-L1 backbone for new combination regimens.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
- Checkpoint Therapeutics files to sell 6.33M shares of common stock for holders
- Checkpoint Therapeutics price target lowered to $8 from $14 at Lake Street
- Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Checkpoint Therapeutics reports Q3 EPS (29c) with items, consensus (76c)